Skip to content
Search

Latest Stories

CMC urges government to review medical cannabis policy

The Centre for Medical Cannabis (CMC) today called on the government to urgently review policy relating to medical cannabis access as a new survey found over 1.4 million people in the UK self-medicating with illicit cannabis.

The survey, published in the report titled 'Left Behind - The Scale of Illegal Cannabis Use for Medical Intent', is the largest ever UK survey showing the extent of the prevalence of use of street-available cannabis for diagnosed medical conditions amongst the general population in England, Wales and Scotland.


According to the detailed breakdown, 653,456 people in the UK are using cannabis for depression; 586,188 for anxiety; 326,728 for chronic pain; 230,631 for arthritis; 182,583 for insomnia and 177,778 for post-traumatic stress disorder (PTSD).

Some 71.4 per cent treating themselves with cannabis are aged between 18 to 44, but a significant 14.6 per cent of users are aged over 55.

The survey further revealed that 42 per cent people using cannabis to treat themselves spend over £100 a month on cannabis, while the highest mean expenditure per month was £357 for Parkinson’s disease.

Steve Moore, Founder of CMC, said: “These findings quantify what we long suspected, almost 3 per cent of the UK adult population are choosing to use cannabis rather than traditional pharmaceutical products to treat their chronic medical conditions.

“We urgently need to know why and can only do so by extending access to cannabis-based medicine and accelerating clinical learning regarding its efficacy. Other countries such as Denmark and France faced with these same challenges have established national medicinal cannabis pilots, we urge the UK government to do likewise.”

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less